ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2367

Characterization of the SFRP4+ PRG4+ Fibroblast Subpopulation in the Dermis of Healthy Skin and Its Relationship to SFRP4+ PRG4- Myofibroblasts in the Skin of Patients with Systemic Sclerosis

Banafsheh Nazari1, Tracy Tabib2 and Robert Lafyatis2, 1University of Pittsburgh, Atlanta, GA, 2University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2023

Keywords: Fibroblasts, Dermal

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2352–2369) Systemic Sclerosis & Related Disorders – Clinical Poster III: Translational Science

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a debilitating autoimmune disease characterized by extensive fibrosis affecting multiple organs. The fibrosis arises from the excessive production of collagen by dysregulated myofibroblasts. Our recent single cell RNA-sequencing (scRNA-seq) studies have described several fibroblast subpopulations in the skin of SSc patients. We have previously shown that myofibroblasts derive from one of these populations that expresses secreted frizzled-related protein 2 (SFRP2) and DPP4, the most common subpopulation of dermal fibroblasts¹. As these cells differentiate into myofibroblasts they show upregulated expression of another gene, secreted frizzled-related protein 4 (SFRP4). However, SFRP4 is also expressed by another fibroblast subpopulation found in healthy as well as SSc skin. ScRNA-seq indicates that this subpopulation also expresses PRG4. Thus, we sought to better understand the location of PRG4+ fibroblasts in healthy skin and their relationship to SFRP4+ myofibroblasts.

Methods: Dorsal forearm skin biopsies were obtained from a cohort of eight SSc patients and twelve healthy controls, following the approved protocol by the Institutional Review Board of the University of Pittsburgh School of Medicine. Paraffin-embedded skin samples were utilized for double and triple immunofluorescence staining, employing Tyramide amplification and a range of antibodies targeting distinct fibroblast markers. High-resolution figures were generated using the Olympus FluoView 3000 confocal microscope.

Results: Our study uncovered a unique subpopulation of fibroblasts characterized by expression of proteoglycan 4 (PRG4) as well as (variable) expression of SFRP4 (and other markers). These cells were seen in both healthy and SSc skin. These cells were located in both papillary and reticular dermis. In contrast, myofibroblasts also expressed secreted frizzled-related protein 4 (SFRP4) and alpha-smooth muscle actin (α-SMA), while lacking the (PRG4) marker. Myofibroblasts were specifically identified in the deep dermis of SSc patients and were not observed in healthy skin.

Conclusion: This study clarifies the relationship between SFRP4-expressing fibroblast subpopulations. PRG4+ fibroblasts do not appear to be myofibroblast progenitors due to previous bioinformatics analyses, as well as their topological distribution in the skin. However, it is likely that they contribute to hydration of skin and intriguing to consider how they may contribute to loss of skin hydration and elasticity with aging, and possibly contribute to other skin pathology. This study also reinforces the importance of the distinct population of α-SMA+ SFRP4+ PRG4- myofibroblasts, which are key cells in driving skin fibrosis and tethering in SSc.

Supporting image 1

Figure 1 shows α-SMA+ SFRP4+ PRG4- myofibroblasts in the dermis of SSc patients

Supporting image 2

Figure 2 shows a higher magnification of α-SMA+ SFRP4+ PRG4- myofibroblast staining in the dermis of SSc patients


Disclosures: B. Nazari: None; T. Tabib: None; R. Lafyatis: None.

To cite this abstract in AMA style:

Nazari B, Tabib T, Lafyatis R. Characterization of the SFRP4+ PRG4+ Fibroblast Subpopulation in the Dermis of Healthy Skin and Its Relationship to SFRP4+ PRG4- Myofibroblasts in the Skin of Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/characterization-of-the-sfrp4-prg4-fibroblast-subpopulation-in-the-dermis-of-healthy-skin-and-its-relationship-to-sfrp4-prg4-myofibroblasts-in-the-skin-of-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-the-sfrp4-prg4-fibroblast-subpopulation-in-the-dermis-of-healthy-skin-and-its-relationship-to-sfrp4-prg4-myofibroblasts-in-the-skin-of-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology